As anyone who's received a drugstore cologne gift set well knows, even Santa Claus gets it wrong sometimes. Hence the throng of customers who flock to shopping malls soon after the holidays to exchange or return less-than-ideal presents. A recent National Retail Federation survey of 60 merchant loss-prevention executives estimated that fraud related to...» Read More
CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.
CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.
CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.
The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.
Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.
Incyte CEO Herve Hoppenot, provides insight to his company's progress on cancer research at this year's ASCO conference.
Ariad Pharmaceuticals CEO Dr. Harvey Berger, says investors are responding to his company's better overall picture, and the progress on its leukemia drug Iclusig.
In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.
Costco reported third-quarter results below analysts' estimates hurt by an increase in merchandise costs and other expenses.
CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.
CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.
PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.
CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.
Lawmakers in four states are considering changing the rules to allow terminally ill people access to experimental drugs before they have FDA approval. Kenneth Goodman, University of Miami, thinks this would be a bad bet for patients. Miles Nadal, MDC Partners Chairman & CEO, weighs in.
CNBC's Meg Tirrell spoke with Merck Chairman & CEO Ken Frazier about the company's decision to sell its over the counter health care products to Bayer.
Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.
Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.
GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.